You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

33 search results for: itch

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)
Infographic

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Dermatology
An infographic describing the etiology, epidemiology, challenges in diagnosis and patient burden of CPUO.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Dermatology
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
View more
Importance of Barrier Dysfunction in Driving AD Pathophysiology
expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

Dermatology
The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.
View more
Role of Type 2 Inflammation in Chronic Inflammatory Diseases
expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

Dermatology
Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023
View more
Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.
View more
Type 2 Inflammation Within Skin Tissue in AD
expert video

Type 2 Inflammation Within Skin Tissue in AD

Dermatology
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.
View more
The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

Dermatology
Dr. Lisa Beck talks about sweat duct dysfunction and the impact of S. aureus colonization.
View more
Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU
expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Dermatology
Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region